Von Willebrand disease: Difference between revisions
Ostermayer (talk | contribs) |
|||
(15 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Most common inherited bleeding disorder | *Abbreviation: vWD | ||
*Most common inherited bleeding disorder<ref>Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 7e (2010), Chapter 230. Hemophilias and Von Willebrand Disease </ref> | |||
*vWF has two roles: | *vWF has two roles: | ||
**1. Acts as cofactor for platelet adhesion | **1. Acts as cofactor for platelet adhesion | ||
Line 14: | Line 15: | ||
{{Increased bleeding DDX}} | {{Increased bleeding DDX}} | ||
== | ==Evaluation== | ||
*Platelet count: normal | |||
*Bleeding time: prolonged | *Bleeding time: prolonged | ||
*PT: normal | *PT: normal | ||
Line 20: | Line 22: | ||
*vWF activity level: low | *vWF activity level: low | ||
== | ==Management== | ||
*Avoid ASA, NSAIDs, heparin | *Avoid ASA, NSAIDs, heparin and coordinate with hematology prior to any invasive or surgical procedures. | ||
===Intermediate | *Multiple therapeutic options exist for prophylaxis or treatment of bleeding. The majority of therapy utilizes Humate-P and/or [[desmopressin]] | ||
* | |||
* | ===Intermediate-Purity Factor VIII=== | ||
====Humate-p==== | |||
''VWF and factor VIII concentration is the first line therapy for vWD bleeding patients. It is contraindicated for any patient with prior history of [[anaphylaxis]] to Humate-p'' | |||
*Loading dose 40 to 60 IU/kg, then 40 to 50 IU/kg every 8 to 12 hours for 3 days to keep the trough level of VWF:RCo >50%; then 40 to 50 IU/kg daily for a total of up to 7 days of treatment. <ref> Humate-P dosing http://www.humate-p.com/DOCS/HumateP-Dosage-PI.pdf</ref> | |||
*For severe bleeding the loading dose is increased to 50 to 75 IU/kg | |||
====Wilate==== | |||
{| {{table}} | |||
| align="center" style="background:#f0f0f0;"|'''Type of Hemorrhages/Surgery''' | |||
| align="center" style="background:#f0f0f0;"|'''Loading Dosage (IU VWF:RCo/ kg BW)''' | |||
| align="center" style="background:#f0f0f0;"|'''Maintenance Dosage (IU VWF:RCo/ kg BW)''' | |||
| align="center" style="background:#f0f0f0;"|'''Therapeutic Goal''' | |||
|- | |||
| Minor Hemorrhages||20-40 IU/kg||20-30 IU/kg every 12-24 hours||VWF:RCo and FVIII activity trough levels of >30% | |||
|- | |||
| Major Hemorrhages||40-60 IU/kg||20-40 IU/kg every 12-24 hours||VWF:RCo and FVIII activity trough levels of >50% | |||
|- | |||
| Minor Surgeries||30-60 IU/kg||15-30 IU/kg or half the loading||VWF:RCo peak level of 50% after loading dose | |||
|} | |||
===Platelet transfusion=== | ===Platelet transfusion=== | ||
*Consider if replacement therapy instituted and persistent bleeding | *Consider if replacement therapy instituted and persistent bleeding | ||
Line 43: | Line 63: | ||
| align="center" style="background:#f0f0f0;"|'''Procedures''' | | align="center" style="background:#f0f0f0;"|'''Procedures''' | ||
|- | |- | ||
| Type 1 ||Low levels of all proteins ||Desmopressin ||rowspan="8"|Desmopressin Responsive: <br>Infuse 0.3 ug/kg to end 45 minutes before procedure. May repeat every 24 hours. | | Type 1 ||Low levels of all proteins ||Desmopressin ||rowspan="8"|'''Desmopressin Responsive:''' <br>Infuse 0.3 ug/kg to end 45 minutes before procedure. May repeat every 24 hours. | ||
<br>For major procedures follow factor VIII levels with plan to keep troughs over 80% <br>Not desmopressin responsive:<br>Humate-P to achieve peak over 120% and troughs of 80%. Levels below 30%: 40-50 IU/kg followed by 20 IU/kg every 12 hours<br>Levels above 30%: 20-40 IU/kg every day <br> | <br>For major procedures follow factor VIII levels with plan to keep troughs over 80%<br> <br>'''Not desmopressin responsive:'''<br>Humate-P to achieve peak over 120% and troughs of 80%.<br><br> Levels below 30%: 40-50 IU/kg followed by 20 IU/kg every 12 hours<br><br>Levels above 30%: 20-40 IU/kg every day <br> | ||
|- | |- | ||
| Type 2 ||Abnormal protein || | | Type 2 ||Abnormal protein || | ||
|- | |- | ||
| Type 2A ||Abnormal protein leading to lower levels of high weight multimers ||Desmopressin (only effective in 10%), | | Type 2A ||Abnormal protein leading to lower levels of high weight multimers ||Desmopressin (only effective in 10%), Intermediate-Purity Factor VIII | ||
|- | |- | ||
| Type 2B ||Abnormal protein with increased binding to gpIIb leading to lower levels of high weight multimers || | | Type 2B ||Abnormal protein with increased binding to gpIIb leading to lower levels of high weight multimers ||Intermediate-Purity Factor VIII | ||
|- | |- | ||
| Type 2N ||Lack of Factor VIII binding site leading to low Factor VIII levels ||Desmopressin | | Type 2N ||Lack of Factor VIII binding site leading to low Factor VIII levels ||Desmopressin | ||
|- | |- | ||
| Type 2M ||Abnormal protein but normal multimer size || | | Type 2M ||Abnormal protein but normal multimer size ||Intermediate-Purity Factor VIII | ||
|- | |- | ||
| Type 3 ||No von Willebrand or Factor VIII present || | | Type 3 ||No von Willebrand or Factor VIII present ||Intermediate-Purity Factor VIII | ||
|- | |- | ||
| Pseudo Von Willebrand (platelet-type) ||Abnormal gpIIb leading to lower levels of high molecular weight multimers ||Platelets + | | Pseudo Von Willebrand (platelet-type) ||Abnormal gpIIb leading to lower levels of high molecular weight multimers ||Platelets + Intermediate-Purity Factor VIII, rVIIa | ||
|- | |- | ||
|} | |} | ||
==Disposition== | |||
==See Also== | ==See Also== | ||
*[[Coagulopathy (Main)]] | |||
==References== | ==References== | ||
<references/> | |||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] |
Revision as of 21:03, 27 June 2017
Background
- Abbreviation: vWD
- Most common inherited bleeding disorder[1]
- vWF has two roles:
- 1. Acts as cofactor for platelet adhesion
- 2. Acts as carrier protein for factor VIII extending its half life
- vWD results from quantitative or qualitative dysfunction of Von Willebrand factor
Clinical Features
- Skin and mucosal bleeding
- Epistaxis, gingival bleeding, menorrhagia
- Hemarthrosis is unusual
Differential Diagnosis
Coagulopathy
Platelet Related
- Too few
- Nonfunctional
Factor Related
- Acquired (Drug Related)
- Warfarin (Coumadin)
- Unfractionated heparin
- Low molecular weight heparin (i.e. enoxaparin (Lovenox), dalteparin)
- Factor Xa Inhibitors (e.g. rivaroxaban, apixaban, fondaparinux, edoxaban)
- Direct thrombin inhibitors (e.g. dabigatran, argatroban, bivalirudin)
- Illness induced
- Genetic
Evaluation
- Platelet count: normal
- Bleeding time: prolonged
- PT: normal
- PTT: normal-mildly prolonged
- vWF activity level: low
Management
- Avoid ASA, NSAIDs, heparin and coordinate with hematology prior to any invasive or surgical procedures.
- Multiple therapeutic options exist for prophylaxis or treatment of bleeding. The majority of therapy utilizes Humate-P and/or desmopressin
Intermediate-Purity Factor VIII
Humate-p
VWF and factor VIII concentration is the first line therapy for vWD bleeding patients. It is contraindicated for any patient with prior history of anaphylaxis to Humate-p
- Loading dose 40 to 60 IU/kg, then 40 to 50 IU/kg every 8 to 12 hours for 3 days to keep the trough level of VWF:RCo >50%; then 40 to 50 IU/kg daily for a total of up to 7 days of treatment. [2]
- For severe bleeding the loading dose is increased to 50 to 75 IU/kg
Wilate
Type of Hemorrhages/Surgery | Loading Dosage (IU VWF:RCo/ kg BW) | Maintenance Dosage (IU VWF:RCo/ kg BW) | Therapeutic Goal |
Minor Hemorrhages | 20-40 IU/kg | 20-30 IU/kg every 12-24 hours | VWF:RCo and FVIII activity trough levels of >30% |
Major Hemorrhages | 40-60 IU/kg | 20-40 IU/kg every 12-24 hours | VWF:RCo and FVIII activity trough levels of >50% |
Minor Surgeries | 30-60 IU/kg | 15-30 IU/kg or half the loading | VWF:RCo peak level of 50% after loading dose |
Platelet transfusion
- Consider if replacement therapy instituted and persistent bleeding
Desmopressin
- Induces release of vWF from endothelial storage sites
- 0.3mcg/kg IV (max 20mcg) over 30min
Aminocaproic acid (Amicar)
- Analogue of the amino acid lysine making it an inhibitor for proteolytic enzymes like plasmin, the enzyme responsible for fibrinolysis.
Recombinant Factor VIIa
- Consider in type 3 VWD patients who have developed antibodies to VWF replacement
- Increased risk of thrombosis, especially in patients with coronary artery disease
Types of Von Willebrand Disease | Pathophysiology | Therapy | Procedures |
Type 1 | Low levels of all proteins | Desmopressin | Desmopressin Responsive: Infuse 0.3 ug/kg to end 45 minutes before procedure. May repeat every 24 hours.
|
Type 2 | Abnormal protein | ||
Type 2A | Abnormal protein leading to lower levels of high weight multimers | Desmopressin (only effective in 10%), Intermediate-Purity Factor VIII | |
Type 2B | Abnormal protein with increased binding to gpIIb leading to lower levels of high weight multimers | Intermediate-Purity Factor VIII | |
Type 2N | Lack of Factor VIII binding site leading to low Factor VIII levels | Desmopressin | |
Type 2M | Abnormal protein but normal multimer size | Intermediate-Purity Factor VIII | |
Type 3 | No von Willebrand or Factor VIII present | Intermediate-Purity Factor VIII | |
Pseudo Von Willebrand (platelet-type) | Abnormal gpIIb leading to lower levels of high molecular weight multimers | Platelets + Intermediate-Purity Factor VIII, rVIIa |
Disposition
See Also
References
- ↑ Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 7e (2010), Chapter 230. Hemophilias and Von Willebrand Disease
- ↑ Humate-P dosing http://www.humate-p.com/DOCS/HumateP-Dosage-PI.pdf